Molecular profiling identifies at least 3 distinct types of posttransplant lymphoproliferative disorder involving the CNS
TO THE EDITOR:
Related Articles
Sinonasal DLBCL: molecular profiling identifies subtypes with distinctive prognosis and targetable genetic features
ABC and GCB subtype sinonasal DLBCL are geno- and phenotypically distinct entities, exhibiting a contrasting disease course and prognosis.ABC subtype sinon
A molecular circuit linking the BCR to the NAD biosynthetic enzyme NAMPT is an actionable target in Richter syndrome
BCR cross-linking activates a positive feedback loop including NAMPT and sirtuins and converging on AKT activation.PI3Kγ/δ and NAMPT inhibitors synergize i
Tyrosine kinase inhibitor resistance in de novo BCR::ABL1–positive BCP-ALL beyond kinase domain mutations
Imatinib resistance at diagnosis was higher in cells of patients who relapsed vs those in remission after imatinib and chemotherapy.Low levels of BCR::ABL1
A human anti-matriptase-2 antibody limits iron overload, α-globin aggregates, and splenomegaly in β-thalassemic mice
RLYB331 is a human antibody that increases hepcidin, reduces iron overload, and ameliorates ineffective erythropoiesis in β-thalassemiaCombination with RAP
Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study
A relationship between low baseline DOAC levels and thrombotic events in 1-year follow-up was found.Early measurement allows the identification of patients
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia
Continuous venetoclax monotherapy for untreated or R/R del(17p) CLL led to a median PFS of 28.2 months and median OS of 62.5 months.Subgroup analysis sugge
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial
There was no clear survival benefit for guadecitabine over standard-of-care in patients with relapsed/refractory AML.Guadecitabine produced higher clinical
Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia
Pediatric MLLT10+ AML have poor prognosis and may benefit from targeted therapies.Patients with PICALM::MLLT10+ and X::MLLT10+ exhibit DNA hypermethylation
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis
After initial clinical response, flares of acute GVHD are common and associated with higher NRM.MAGIC biomarkers at first CR/VGPR can predict GVHD flares.
Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease
Recurrence of VOC requiring hospitalization or treatment occurs in 8.7% of patients after HCT with stable donor engraftment in SCD.GF, age at HCT, prior hi